© Globe Newswire
06.06.2025
ZEAL
LISTED
CPH
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
News Preview
Company announcement – No. 14 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
FAGR
LISTED
EURONEXT
Fagron increases share capital through exercise subscription rights
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET...
Themefolio
Profiler
Peergroup
© PR Newswire
06.06.2025
SOBI
LISTED
STO
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
News Preview
STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).The data were presented as p...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
06.06.2025
RXRX
LISTED
NASDAQ
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
News Preview
Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company Recursion (NASDAQ: RXRX), today announced the open-source release of Boltz-2, a first of its kind biomolecular foundation model....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.06.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
GXI
LISTED
XETR
Annual General Meeting approves key proposed resolutions by a large majority
News Preview
Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority
2024: Progress on key strategic topics
Long-term outlook remains positve thanks to the successfull transformation into a system and solution provider
Dividend of EUR 0.04 per share
Duesseldorf, June 5, 2025. The Annual General Meeting of Gerresheimer AG......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
GXI
LISTED
XETR
Hauptversammlung stimmt mit großer Mehrheit wesentlichen Beschlussvorschläge zu
News Preview
Gerresheimer AG: Hauptversammlung stimmt mit großer Mehrheit wesentlichen Beschlussvorschläge zu
2024: Fortschritte bei wichtigen strategischen Themen
Langfristig unverändert positiver Ausblick durch erfolgreiche Transformation zum System- und Lösungsanbieter
Dividende von 0,04 EUR je Aktie
Düsseldorf, 5. Juni 2025. Die Hauptversammlung der Gerr......
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
CU6
LISTED
ASX
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
News Preview
HIGHLIGHTS
Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs).DISCO compared the diagnostic performance of 64Cu-SARTATE at an average of 4 hours (between 3 to 5 hours) an...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
LIVN
LISTED
NASDAQ
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
LIVN
LISTED
NASDAQ
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1.
Several CORE-VNS study findings were highlighted in the recent article on GTC se...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
SLP
LISTED
NASDAQ
Simulations Plus Releases ADMET Predictor® 13
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, op...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
05.06.2025
EUZ
LISTED
XETR
Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
News Preview
Berlin, Germany, 05 June 2025. Eckert & Ziegler (ISIN DE0005659700, TecDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor.
With......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
EUZ
LISTED
XETR
Illuccix® PSMA-PET Diagnostik erhält Zulassung in Deutschland
News Preview
Berlin, Deutschland, 05. Juni 2025. Eckert & Ziegler (ISIN DE0005659700, TecDAX) gratuliert Telix Pharmaceuticals Limited (Telix) zur Zulassung ihres Prostatakrebs-PET-Bildgebungsmittels Illuccix® (Kit zur Herstellung von Gallium-68-Gozetotid-Injektion) in Deutschland, in dem die Eckert & Ziegler Radiopharma GmbH offizieller Vertriebspartne......
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
SECT_B
LISTED
STO
Sectra's year-end report 2024/2025: Reporting solid growth in a time of change
News Preview
LINKÖPING, Sweden, June 5, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is continuing to deliver results through high customer satisfaction, innovation and the ongoing transition to service deliveries. With significant advances in medical IT and cybersecurity, growing market shares and innov...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
SECT_B
LISTED
STO
Sectra's year-end report 2024/2025: Reporting solid growth in a time of change
News Preview
LINKÖPING, Sweden, June 5, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is continuing to deliver results through high customer satisfaction, innovation and the ongoing transition to service deliveries. With significant advances in medical IT and cybersecurity, growing market shares and innov...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
FYB
LISTED
XETR
Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
News Preview
Press Release // June 5, 2025
Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Raniviso® becomes first approved Lucentis® biosimilar in Brazil
Commercialization partnership established with Brazilian pharmaceutical company Biomm
Product launch in Brazil expected in Q4 2025, kicking off the commercial rollout of FYB201......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.06.2025
FYB
LISTED
XETR
Lucentis®-Biosimilar FYB201/Ranivisio® (Ranibizumab) in Brasilien zugelassen
News Preview
Pressemitteilung // 05. Juni 2025
Lucentis®-Biosimilar FYB201/Ranivisio® (Ranibizumab) in Brasilien zugelassen
Raniviso® als erstes Lucentis®-Biosimilar in Brasilien zugelassen
Kommerzialisierungspartnerschaft mit brasilianischem Pharmaunternehmen Biomm abgeschlossen
Produkteinführung in Brasilien ist für das vierte Quartal 2025 geplant und b......
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
ERF
LISTED
EURONEXT
Eurofins Consumer Product Testing Announces State-of-the-Art Expansion of Bangalore Laboratory
News Preview
The Eurofins Consumer Product Testing network of laboratories in India recently unveiled its expanded, state-of-the-art facilities in Hongasandra, Bangalore. This strategic investment doubles the Bangalore laboratory’s footprint and offers enhanced capabilities, enabling a significant leap in compliance and performance testing tailored to the evol...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
DBV
LISTED
EURONEXT
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
News Preview
Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025...
Themefolio
Profiler
Peergroup
© ActuNews
04.06.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
04.06.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 100.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
04.06.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – June 4, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on June 3, 2025, from Atlas Sp...
Themefolio
Profiler
Peergroup
© ActuNews
04.06.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 4 juni 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantie...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
CLARI
LISTED
EURONEXT
Renewal of the drawdown under the Revolving Credit Facility for a six-month period
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
EAPI
LISTED
EURONEXT
Frédéric Robert appointed EUROAPI’s Chief Commercial Officer overseeing API Solutions and CDMO activities
News Preview
Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.06.2025
1SXP
LISTED
XETR
SCHOTT Pharma invests in sterile cartridge production in Hungary
News Preview
SCHOTT Pharma invests in sterile cartridge production in Hungary
June 4, 2025, Hungary, Lukácsháza
SCHOTT Pharma breaks ground for a new production facility for ready-to-use cartridges in Hungary
Its investment of over EUR 100 million is part of the company’s expansion strategy to meet the growing market demand for high-value solutions
The new ......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.06.2025
1SXP
LISTED
XETR
SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn
News Preview
SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn
4. Juni 2025, Lukácsháza, Ungarn
SCHOTT Pharma beginnt mit dem Bau einer neuen Produktionsstätte für gebrauchsfertige Karpulen in Ungarn
Die Investition von über 100 Millionen Euro ist Teil der Expansionsstrategie des Unternehmens, um der wachsenden Nachfrage nach High-Value-......
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
LIVN
LISTED
NASDAQ
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process fo...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
SOBI
LISTED
STO
Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
News Preview
STOCKHOLM, June 4, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will have a strong scientific presence at this year's ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters. We are proud that two of our abstracts have been recognised in the top 10 abstracts at ERA 2025, as selected by expert review...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets
News Preview
STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated s...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
News Preview
Documents made available to the shareholders for the combined general meeting of June 25th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
News Preview
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
IBAB
LISTED
EURONEXT
World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care
News Preview
New global education initiative unveiled at 2025 PTCOG Annual Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
ATAI
LISTED
NASDAQ
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Atai Life Sciences N.V. (NASDAQ: ATAI) and Beckley Psytech Limited is fair to Atai shareholders.
Halper Sadeh encourages Atai shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
ORNBV
LISTED
HEL
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
News Preview
ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
DBV
LISTED
EURONEXT
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
News Preview
Châtillon, France, June 03, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
CAMX
LISTED
STO
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
News Preview
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compoundsCamurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royaltyLUND, Sweden and INDIANAPOLIS, June 3, 2025 /PRNewswire/ -- Camurus (NASDA...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
CAMX
LISTED
STO
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
News Preview
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compoundsCamurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royaltyLUND, Sweden and INDIANAPOLIS, June 3, 2025 /PRNewswire/ -- Camurus (NASDA...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.06.2025
EVT
LISTED
XETR
Ergebnisse der Hauptversammlung 2025
News Preview
Alle Tagesordnungspunkte angenommen
Unter dem Motto „Pioneering Drug Discovery – Wegweisende Arzneimittelforschung“ stellte CEO Dr. Christian Wojczewski die aktuelle Situation und den strategischen Ausblick von Evotec vor
46,45 % des eingetragenen Grundkapitals vertreten
Hamburg, 03. Juni 2025:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/Te......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.06.2025
EVT
LISTED
XETR
Results of the Annual General Meeting 2025
News Preview
All agenda items adopted
Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook
46.45% of the registered share capital represented
Hamburg, Germany, 03 June 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that ......
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
LEGN
LISTED
NASDAQ
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
News Preview
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.06.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - von First Berlin Equity Research GmbH
03.06.2025 / 14:27 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
HELP
LISTED
NASDAQ
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
SOBI
LISTED
STO
Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
News Preview
VALIANT Phase 3 data in nephrology after presentation at the ERA congress.
STOCKHOLM, June 3, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference call on Thursday, 12 June, at 13:30 CEST, 12:30 GMT, and 08:30 EDT. The call will include a presentation of results and insights from management and Professor...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
OXB
LISTED
LSE
OXB Highlights the Launch of its Innovation and Technology Excellence Board
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
TRAW
LISTED
NASDAQ
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
News Preview
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
PHM
LISTED
BME
PharmaMar präsentiert auf der ASCO dass Zepzelca® (lurbinectedin) in Kombination mit Atezolizumab (Tecentriq®) das Überleben als Erstlinien-Erhaltungstherapie bei kleinzelligem Lungenkrebs
News Preview
Die Erstlinien-Erhaltungskombinationstherapie verringerte das Risiko eines Fortschreitens der Krankheit oder des Todes um 46%, mit einer medianen Gesamtüberlebenszeit von 13,2 Monaten gegenüber der 10,6 Monaten für Atezolizumab allein, ab dem Zeitpunkt der RandomisierungErste Phase-3-Studie, die statistisch signifikante und klinisch bedeutsame Ve...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
PHM
LISTED
BME
PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer
News Preview
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomizationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and over...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
QGEN
LISTED
NYSE
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
News Preview
BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARIT...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ICLR
LISTED
NASDAQ
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
GMAB
LISTED
CPH
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
News Preview
Media ReleaseCOPENHAGEN, Denmark; June 2, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ORX
LISTED
STO
Orexo to present clinical data for OX640 at the EAACI Congress
News Preview
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI is a leading global association devoted to allergic and immunology diseasesOrexo´s advisor Dr. Anne K Ellis, Professor and Chair of the Division of Allerg...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ORX
LISTED
STO
Orexo to present clinical data for OX640 at the EAACI Congress
News Preview
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI is a leading global association devoted to allergic and immunology diseasesOrexo´s advisor Dr. Anne K Ellis, Professor and Chair of the Division of Allerg...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
News Preview
bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
TEM
LISTED
NASDAQ
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest additi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
RAY B
LISTED
STO
RaySearch to present advanced software innovations for particle therapy at PTCOG 63
News Preview
STOCKHOLM, June 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) will exhibit at PTCOG 63, held June 3-6, 2025, in Buenos Aires, Argentina. At booth #08, the company will showcase its latest software innovations driving the future of particle therapy.
RaySearch's portfolio – including RayStation®*, RayCare®*, RayIntelligence®, and RayCom...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ZLAB
LISTED
NASDAQ
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company’s potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.06.2025
GXI
LISTED
XETR
Gerresheimer Adjusts Guidance for Financial Year 2025
News Preview
Gerresheimer Adjusts Guidance for Financial Year 2025
Preliminary results for Q2 2025: Low-single-digit organic revenue growth, adjusted EBITDA margin around 19%
Continued subdued demand in the cosmetics market
Temporary decline in demand for containment solutions for oral liquid medications
New dividend proposal of 4% of share capital
Long-te......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
